Tesamorelin (EGRIFTA): What the Clinical Data Actually Shows

Last updated: April 2026. We review this article quarterly as new clinical data becomes available.

You've probably heard of sermorelin, CJC-1295, ipamorelin. The gray-market GHRH peptides that doctors in performance medicine circles talk about quietly, and Reddit threads discuss loudly.

Tesamorelin is different from all of them. It's the only growth hormone-releasing hormone analog that went through full Phase 3 clinical trials, earned FDA approval, and got its own brand name (EGRIFTA SV). That distinction matters for both what the evidence shows and for how you can access it.

But "FDA-approved" doesn't mean "approved for whatever you want to use it for." Tesamorelin's approval is narrow and specific. The off-label interest is wide and growing. Understanding the gap between those two things is exactly what this guide covers.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals your pituitary to release growth hormone. It's not growth hormone itself. It tells your body to produce its own, working through the same physiological pathway your hypothalamus uses every night.

Structurally, tesamorelin is a stabilized form of GHRH(1-44), the full 44-amino acid sequence with a trans-3-hexenoic acid modification at the N-terminus. That modification was the breakthrough: it makes the peptide more resistant to enzymatic degradation, giving it a longer functional half-life than native GHRH. The brand name EGRIFTA SV (from manufacturer Theratechnologies) received FDA approval in November 2010, making it the first GHRH analog approved in the United States (Spooner & Olin, 2012).

What it does mechanically: bind to GHRH receptors in the pituitary, trigger pulsatile growth hormone release, drive IGF-1 production in the liver, and from there influence fat metabolism, muscle preservation, and several other downstream processes. The pulsatile pattern matters because it mimics how natural GH secretion works, not the sustained supraphysiologic flood you'd get from exogenous HGH.

Dr. Greg Jones, reviewing the mechanism in a 2026 walkthrough, described it clearly: "Tesamorelin is the messenger. Growth hormone is the signal. IGF-1 is the builder. Together they help regulate metabolism, promote fat breakdown, support muscle tone and influence everything from collagen synthesis to cognitive health." (Jones, 2026)

The FDA Approval: Read This Section Carefully

The EGRIFTA SV label is explicit on what tesamorelin is and is not approved for. Here it is verbatim:

"EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."

That's it. One population. One condition. HIV-associated lipodystrophy is the fat redistribution syndrome that many patients develop from long-term antiretroviral therapy. It involves central fat accumulation (belly fat), sometimes combined with peripheral fat loss.

The label also specifies three limitations of use:

• Long-term cardiovascular safety of EGRIFTA SV has not been established
• EGRIFTA SV is not indicated for weight loss management, as it has a weight neutral effect
• There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV

That second limitation trips people up. If you're searching "tesamorelin for weight loss" expecting dramatic scale movement, the FDA label directly addresses that: weight neutral. Visceral fat goes down significantly in the trials. Total body weight does not change much, because lean mass and subcutaneous fat remain stable. That's mechanistically different from the kind of fat loss patients think about on semaglutide or tirzepatide.

Everything outside of HIV-associated lipodystrophy (general visceral fat reduction, performance enhancement, body composition optimization in metabolically healthy people) is off-label use. Physicians can prescribe off-label legally, but they're working without the same evidence base that supported FDA approval.

What the Clinical Trials Actually Found

This is where tesamorelin genuinely separates from the gray-market GHRH stack. The data isn't based on a few small studies. It's based on Phase 3 randomized controlled trials, pooled analyses, and follow-on research from groups at Harvard, MGH, and UCSD.

The Phase 3 Trials: Visceral Fat Reduction

The pivotal data came from (Falutz, 2010), a randomized, placebo-controlled trial of 404 HIV-infected patients with excess abdominal fat conducted over 12 months published in JAIDS (DOI: 10.1097/QAI.0b013e3181cbdaff). In the primary efficacy phase (months 0-6), patients received tesamorelin 2 mg subcutaneously daily or placebo in a 2:1 ratio. Visceral adipose tissue (VAT) measured by CT scan decreased by 10.9% in the tesamorelin group versus 0.6% in the placebo group (P < 0.0001). Trunk fat, waist circumference, and waist-hip ratio all improved. Subcutaneous fat did not change, which confirmed the selective visceral effect.

The same group published a pooled analysis of two Phase 3 studies covering 806 patients (Falutz et al., 2010, JCEM, DOI: 10.1210/jc.2010-0490). At week 26, VAT decreased by an average of 24 cm² in the tesamorelin group versus an increase of 2 cm² in the placebo group (treatment effect: -15.4%, P < 0.001). Triglycerides also decreased significantly in the treated group.

To put those numbers in real terms: a 15% reduction in visceral fat cross-sectional area measured by CT is clinically meaningful (Falutz et al., 2010). It's the kind of reduction associated with improved cardiovascular risk markers, better insulin sensitivity, and reduced inflammatory burden. It's not a number that shows up on a bathroom scale, but it's not meaningless. It's measurable change in the organ fat that actually drives metabolic risk.

The JAMA Trial: Visceral Fat and Liver Fat Together

(Stanley et al., 2014) published what may be the most important single tesamorelin study in JAMA (DOI: 10.1001/jama.2014.8334). This double-blind, randomized, placebo-controlled trial at Massachusetts General Hospital enrolled 50 HIV-infected men and women with abdominal fat accumulation and randomized them to tesamorelin 2 mg daily versus placebo for 6 months. The trial had two primary endpoints: visceral fat and liver fat.

The visceral fat result confirmed the Phase 3 data. Mean change was -34 cm² with tesamorelin versus +8 cm² with placebo (treatment effect: -42 cm², 95% CI -71 to -14 cm², P = 0.005).

The liver fat finding was new. Tesamorelin significantly reduced liver fat fraction (measured by MR spectroscopy) compared to placebo (P = 0.003). That's significant because visceral adiposity and NAFLD are closely linked. Patients who accumulate visceral fat often accumulate liver fat simultaneously, and liver fat in HIV patients is a major driver of metabolic dysfunction. This was the first trial demonstrating tesamorelin's effect on both compartments together (Stanley et al., 2014).

Subsequent work (Fourman et al., 2017, AIDS, DOI: 10.1097/QAD.0000000000001614) confirmed that visceral fat responders (patients who achieved at least 8% VAT reduction) also showed meaningful improvements in liver enzymes ALT and AST. The benefit was tied to how much visceral fat actually came down.

The JAMA Neurology Trial: Cognitive Effects

(Friedman et al., 2013, JAMA Neurology, DOI: 10.1001/jamaneurol.2013.1425) explored a different angle: whether GHRH signaling affects brain neurochemistry in aging adults. Thirty adults including 17 with mild cognitive impairment received tesamorelin 1 mg daily or placebo for 20 weeks, with brain MR spectroscopy and cognitive testing at baseline, week 10, and week 20.

The key finding: tesamorelin increased brain GABA levels in multiple regions, and this change was associated with improvements in cognitive performance (Friedman et al., 2013). GABA is the brain's primary inhibitory neurotransmitter; lower GABA activity is associated with the cognitive slowing seen in aging and early neurodegeneration.

This is preliminary data. The trial enrolled only 30 participants, and it wasn't designed to prove cognitive benefit. But it's real controlled-trial data from a credible research group, and it's one of the reasons tesamorelin gets attention outside HIV medicine.

The Diabetes Safety Study

(Clemmons et al., 2017, PLOS ONE, DOI: 10.1371/journal.pone.0179538) ran a 12-week randomized, placebo-controlled study in 53 patients with Type 2 diabetes, specifically designed to answer whether tesamorelin alters insulin sensitivity or glycemic control. Three groups: placebo, 1 mg tesamorelin, 2 mg tesamorelin.

Result: no significant differences in relative insulin response, fasting glucose, or HbA1c between groups over 12 weeks (Clemmons et al., 2017). Total cholesterol and non-HDL cholesterol decreased significantly in the 2 mg group (P < 0.05 vs placebo). This matters because GH secretagogues raise some insulin resistance concerns. Tesamorelin, at least over 12 weeks in T2D patients, did not worsen glycemic control.

How Tesamorelin Works: The GHRH Mechanism

Understanding why tesamorelin produces these specific results requires understanding how GHRH works in the first place.

Growth hormone is not secreted continuously. It's released in pulses, primarily during slow-wave sleep and in response to exercise and fasting. Each pulse is triggered by GHRH from the hypothalamus, which signals pituitary somatotrophs to release stored GH. That GH pulse then reaches the liver and peripheral tissues, where it drives IGF-1 production and activates fat metabolism through lipolysis.

As we age, GHRH pulse amplitude decreases. GH secretion drops. IGF-1 falls. Visceral fat accumulates partly because the GH-IGF-1 axis is no longer keeping up with the metabolic work it did in younger years. In HIV patients specifically, this GH axis suppression is exaggerated by the metabolic effects of antiretroviral therapy, producing the lipodystrophy pattern (Bedimo, 2011).

Tesamorelin works by restoring GHRH signaling, not flooding the system with exogenous hormone. It re-activates the physiological trigger that drives pulsatile GH release. The result is more natural-pattern GH secretion than you'd get from injecting recombinant HGH directly (Wang & Tomlinson, 2009). Your body's own feedback loops (specifically somatostatin, which suppresses GH when levels get too high) remain intact, which is one of the key safety arguments for GHRH analogs versus direct GH administration.

Tesamorelin Dosage: What the FDA Label Says

The EGRIFTA SV prescribing information specifies a single approved dose:

1.4 mg (0.35 mL of reconstituted solution) injected subcutaneously once daily.

This is specific to the EGRIFTA SV (2 mg per vial) formulation. The original EGRIFTA (1 mg per vial) had a different dose and different reconstitution instructions. The two products are not interchangeable.

Injection site: abdomen, rotating sites. Not into scar tissue, bruises, or the navel.

Reconstitution: dissolve one vial of lyophilized powder with 0.5 mL of sterile water (provided). Roll gently for 30 seconds. Do not shake. Administer 0.35 mL immediately and discard the remaining solution. It's single-use.

For the research on visceral fat in HIV patients, 2 mg daily was the Phase 3 trial dose. The 1.4 mg EGRIFTA SV dose was established in subsequent development as the approved clinical dose for that indication.

Off-label use in non-HIV populations has explored similar dose ranges (typically 1-2 mg daily), often timed for evening or bedtime administration to align with natural GH pulsatility. These dosing strategies reflect clinical experience rather than FDA-approved protocol. If you're exploring tesamorelin outside the HIV-lipodystrophy indication, the dose and timing need to come from a physician evaluating your specific case.

How to Inject Tesamorelin (EGRIFTA SV)

The EGRIFTA SV prescribing information outlines the injection process:

1. Wash hands and assemble supplies. You'll need the vial of lyophilized powder, the sterile water diluent, an insulin syringe (27g or 29g), and alcohol pads.
2. Reconstitute the vial. Inject 0.5 mL of sterile water into the vial, roll gently for 30 seconds, and inspect the solution. It should be clear and colorless. Do not shake. Do not use if you see particles or discoloration.
3. Draw 0.35 mL into the syringe. This is the 1.4 mg dose.
4. Clean the injection site with an alcohol pad and let it air-dry.
5. Inject subcutaneously into the abdomen. Pinch the skin, insert at 45-90 degrees depending on tissue depth, inject slowly.
6. Discard the remainder. Any unused solution must be thrown away. This is single-use.
7. Rotate injection sites across different areas of the abdomen to prevent lipodystrophy at the injection site.

Tesamorelin Results: What to Expect and When

Based on the Phase 3 trial data, the results timeline looks like this:

Weeks 1-4: IGF-1 begins to rise, indicating GH axis activation. Most patients don't notice much outwardly, though some report improved sleep quality in the first few weeks.

Weeks 4-12: Visceral fat reduction begins to become measurable by imaging. Body composition changes on a physical level take more time than IGF-1 changes.

Week 26 (6 months): The primary endpoint in the pivotal trials. In responders, mean VAT reduction of 15-18% from baseline. Waist circumference improvements. In the JAMA trial, meaningful liver fat reduction confirmed at this timepoint.

Weeks 26-52: In patients who continue therapy, the visceral fat reduction is maintained. In the extension phases of the Phase 3 trials, patients who stayed on tesamorelin maintained their VAT reduction, while patients who stopped tesamorelin experienced reaccumulation of visceral fat over the subsequent 26-week withdrawal period.

The reaccumulation finding is important for off-label users to understand. Tesamorelin's effects on visceral fat appear to be treatment-dependent. The fat comes back when you stop. This is different from lifestyle-driven fat loss, which can be maintained. Long-term use raises the question of cost, commitment, and ongoing provider monitoring.

Side Effects and Safety: The Transparent Picture

Clinical Trial Safety Data

In the Phase 3 trials covering 806 patients over 26 weeks, treatment-emergent serious adverse events occurred in fewer than 4% of patients (Dhillon, 2011, Drugs, DOI: 10.2165/11202240-000000000-00000). The most common events were injection-site reactions and known complications of underlying HIV disease.

The key adverse effects from the trial data include:

• Injection site reactions (urticaria, pain, redness, bruising): most common in the first weeks, often self-limiting
• Peripheral edema: fluid retention, especially early in treatment
• Arthralgia and myalgia: joint and muscle pain related to GH axis activation
• Glucose changes: monitored closely given the GH-insulin resistance interaction; the T2D study found no significant worsening at 12 weeks
• Elevated IGF-1: rises predictably with therapy; very high IGF-1 is associated with increased cancer risk in other contexts, though no cancer signal emerged in the tesamorelin trials

FAERS Adverse Event Reports

The FDA's FAERS database (adverse event reports submitted by patients, physicians, and manufacturers) contains 3,356 total reports for tesamorelin, with 100 classified as serious. The most frequently reported adverse reactions include hypoesthesia, paresthesia, injection site urticaria, weight increased, dizziness, urticaria, injection site pain, pain in extremity, injection site reaction, and arthralgia.

These are passive surveillance reports, not incidence rates. You can't calculate how often a side effect occurs from FAERS data. What the 3,356 reports tell you is that tesamorelin has real-world usage volume and a documented signal worth knowing about. The hypoesthesia and paresthesia (numbness and tingling, particularly in the hands) are consistent with the fluid retention and median nerve compression that GH secretagogues can cause.

The Cardiovascular Unknown

The FDA label states: "Long-term cardiovascular safety of EGRIFTA SV has not been established."

This isn't a warning that tesamorelin causes cardiovascular harm. It's an honest acknowledgment that the trials weren't designed or long enough to answer the long-term CV question. The visceral fat reduction itself should theoretically improve cardiovascular risk. But whether the GH axis activation at the doses used tips the risk-benefit ratio over years is genuinely unknown. This is a key reason the FDA specified that physicians should "consider the risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue."

For off-label users without HIV-associated lipodystrophy, the cardiovascular uncertainty is even more pronounced. The trials were conducted in HIV patients with specific metabolic profiles, and extrapolating to other populations involves assumptions the data can't fully support.

Tesamorelin vs. Other GH Peptides

Tesamorelin occupies a specific niche when compared to other peptides that affect the GH axis. Here's how it stacks up:

	Tesamorelin	Sermorelin	CJC-1295 + Ipamorelin
Mechanism	GHRH analog	GHRH analog	GHRH analog + GHRP
FDA status	Approved (HIV-lipodystrophy)	Compounded	Compounded
Primary evidence	Phase 3 RCTs, 800+ patients	Limited human trials	Mainly animal + clinical use
Standard dose	1.4-2 mg daily SC	200-300 mcg nightly SC	Varies by compound
Evidence for visceral fat	Strong (CT-confirmed trials)	Minimal human data	Anecdotal + small studies
Half-life	~30 minutes active; effects persist	~11 minutes	CJC-1295: days (DAC); ipamorelin: ~2 hours
WADA status	Prohibited	Prohibited	Prohibited

The main advantage tesamorelin holds is the evidence base. If you want the peptide with the strongest controlled-trial data for visceral fat, tesamorelin is the answer. If you're considering a GHRH analog for general GH optimization, sleep, or recovery, the evidence base doesn't cleanly distinguish tesamorelin from sermorelin or the CJC/ipamorelin stack. There simply isn't comparative trial data in healthy populations.

Sermorelin is the most commonly compounded alternative. For a detailed look at how it works and what the clinical data shows, see our guide on sermorelin therapy results and before/after outcomes.

WADA Prohibition Status

Tesamorelin is prohibited under WADA's Prohibited List in the category of Growth Hormone Releasing Hormones. Sermorelin, CJC-1295, and tesamorelin are all in this category. WADA's 2026 Prohibited List explicitly mentions these peptides, and testing methods have advanced to detect them in blood samples at pg/mL concentrations (Thomas et al., 2022, DOI: 10.1002/ansa.202200027).

If you're a competitive athlete subject to anti-doping testing, use of tesamorelin violates the World Anti-Doping Code for your sport, whether or not it's physician-prescribed. Therapeutic use exemptions (TUEs) exist but are granted for documented medical need; HIV-associated lipodystrophy would qualify. Optimization goals would not. Verify the current prohibited list at wada-ama.org before use.

Cost, Coverage, and How to Access Tesamorelin

EGRIFTA SV (Brand Name)

EGRIFTA SV is expensive. Without insurance, the monthly cost of brand-name EGRIFTA SV runs several thousand dollars. Theratechnologies (the manufacturer) operates a patient assistance program, and some patients with HIV-associated lipodystrophy obtain coverage through their insurer under the approved indication.

Insurance: Typically only covers EGRIFTA SV for the FDA-approved indication (HIV-associated lipodystrophy with documented abdominal fat accumulation). Patients using it off-label for general body composition purposes generally pay out of pocket.

Theratechnologies offers a savings card program for eligible commercially insured patients. Check their official site for current terms, as these programs change. Their medical affairs team can help navigate prior authorization for approved-indication patients.

Compounded Tesamorelin

Compounded tesamorelin is available through licensed compounding pharmacies and some telehealth platforms. The cost varies significantly, but is generally $100-400/month depending on dose and provider. This is not equivalent to EGRIFTA SV. Compounded peptides don't go through the same manufacturing validation, though reputable pharmacies follow USP standards for sterile compounds.

The FDA's 2024 reclassification of multiple peptides (BPC-157, TB-500, CJC-1295) created significant disruption in the compounding market. Tesamorelin itself retained availability through compounding, but regulatory rules around compounded peptides are active, and access can change.

Accessing Through HEXIS

At HEXIS, we don't start any protocol based on symptoms alone. If you're interested in tesamorelin (or any GHRH analog), your evaluation starts with labs: IGF-1, fasting insulin, glucose, lipid panel, and relevant body composition assessment. The clinical picture tells us whether a GH secretagogue is appropriate and what the dose and monitoring plan should look like.

For patients in Great Falls, MT, or across Montana, Idaho, Washington, and Oregon, we offer both in-clinic and telehealth options. Schedule a consultation and we'll review your labs and goals before making any protocol decision.

Frequently Asked Questions

What is tesamorelin used for?

Tesamorelin is FDA-approved specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy (brand name EGRIFTA SV). Off-label, physicians use it for general visceral fat reduction, GH optimization, and potentially cognitive support in aging populations. The clinical trial data supporting its visceral fat effect is substantially stronger than the evidence base for off-label applications.

How does tesamorelin compare to sermorelin for fat loss?

Tesamorelin has controlled-trial evidence for visceral fat reduction in HIV-associated lipodystrophy — Phase 3 RCTs with CT-confirmed results. Sermorelin lacks equivalent human trial data specifically for fat loss. Both work through GHRH receptor activation. For pure evidence-based confidence in visceral fat reduction, tesamorelin's data is stronger. For general GH support and cost efficiency, sermorelin is often the more accessible choice through fat-loss peptide protocols.

What are the main tesamorelin side effects to watch for?

Injection site reactions (pain, urticaria, redness) are the most common, especially early in treatment. Peripheral edema and joint pain (arthralgia) are also frequently reported — these relate to the fluid-retaining effects of increased GH secretion. Numbness or tingling in the hands (paresthesia) can occur and should be monitored. Glucose and IGF-1 levels warrant periodic lab checks. The FDA FAERS database contains 3,356 total adverse event reports, with 100 classified as serious, confirming the need for physician oversight rather than self-managed use.

Does tesamorelin help with weight loss?

The FDA label is direct: EGRIFTA SV "has a weight neutral effect" and "is not indicated for weight loss management." In the clinical trials, visceral fat decreased significantly but total body weight did not change substantially. This happens because lean mass and subcutaneous fat remain stable. Tesamorelin selectively targets visceral (organ) fat. For significant scale weight loss, GLP-1 medications like Wegovy (semaglutide) operate through a completely different mechanism with substantially larger effects on total body weight.

How long do you need to take tesamorelin to see results?

In the Phase 3 trials, significant visceral fat reduction was documented at 26 weeks (6 months). Some body composition changes are visible earlier, but the primary endpoint in the pivotal studies was at 6 months. Critically, the Phase 3 extension data showed that visceral fat reaccumulates after discontinuation — the effect is not permanent. Ongoing treatment is needed to maintain results. If you haven't achieved measurable VAT reduction by 3-6 months, the FDA label notes that the risk/benefit balance should be reconsidered.

The Bottom Line

Tesamorelin is the most evidence-backed GHRH analog available. Seven tier-1 RCTs. CT-confirmed visceral fat reduction. JAMA-published liver fat data. Cognitive effects under investigation. These are not common credentials for a peptide.

The regulatory picture is narrow — the FDA approval is specifically for HIV-associated lipodystrophy, and the label explicitly states it is not for weight loss and that long-term cardiovascular safety hasn't been established. Off-label use in otherwise healthy adults is medically and legally permissible but means working with a thinner evidence base.

If you're looking at tesamorelin for visceral fat that's affecting your metabolic health, that conversation starts with labs and an honest assessment of where you are. Not with a dose calculator from Reddit.

Schedule a consultation with HEXIS to review whether tesamorelin belongs in your protocol — with your labs, your history, and a physician-guided plan behind it.

---